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The present study determined whether the serotonin2A (5-HT2A)
receptors in the hypothalamic paraventricular nucleus mediate the
neuroendocrine responses to a peripheral injection of the
5-HT2A/2C receptor agonist ()DOI [()1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane]. The 5-HT2A receptor antagonist
MDL100,907 (()--(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl-
ethyl)]-4-piperidinemethanol), the 5-HT2C receptor antagonist
SB-242084 (6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-
pyridyl]carbamoyl]-indoline), or vehicle were microinjected bilater-
ally through a chronically implanted double-barreled cannula into
the hypothalamic paraventricular nucleus 15 min before a periph-
eral injection of ()DOI in conscious rats. ()DOI significantly
elevated plasma levels of oxytocin, prolactin, ACTH, corticoste-
rone, and renin. Neither the 5-HT2A receptor antagonist nor the
5-HT2C receptor antagonist, injected alone, altered the basal lev-
els of these hormones. MDL100,907 (0.748, 7.48, and 18.7 nmol)
dose dependently inhibited the ()DOI-induced increase in all of
the hormones except corticosterone. In contrast, SB-242084 (10
nmol) did not inhibit ()DOI-increased hormone levels. To confirm
the presence of 5-HT2A receptors in the hypothalamic paraven-
tricular nucleus, 5-HT2A receptors were mapped using immuno-
histochemistry. Densely labeled magnocellular neurons were ob-
served throughout the anterior and posterior magnocellular
subdivisions of the hypothalamic paraventricular nucleus. Moder-
ately to densely labeled cells were also observed in parvicellular
regions. Thus, it is likely that 5-HT2A receptors are present on
neuroendocrine cells in the hypothalamic paraventricular nucleus.
These data provide the first direct evidence that neuroendocrine
responses to a peripheral injection of ()DOI are predominantly
mediated by activation of 5-HT2A receptors in the hypothalamic
paraventricular nucleus.
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Serotonin2A/2C (5-HT2A/2C) receptors are involved in the regula-
tion of many physiological functions and are the cellular targets of
drugs used to treat psychiatric disorders, such as depression and
schizophrenia (Price et al., 1997; Sargent et al., 1998; Blier and de
Montigny, 1999; Aghajanian and Marek, 2000). 5-HT2A and
5-HT2C receptors share a large sequence homology and both are
coupled via Gq/11-proteins to phosphoinositide signaling cascades
(Martin and Humphrey, 1994; Barnes and Sharp, 1999). However,
their affinities for serotonin and patterns of distribution in the
brain are different (Hoffman and Mezey, 1989; Appel et al., 1990;
Zifa and Fillion, 1992). Recent data suggest that their signal
transduction mechanisms can be distinguished from each other
(Berg et al., 2001).
()DOI [()1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane],
the most selective 5-HT2A/2C agonist to date, has been used to
study 5-HT2A/2C receptor-mediated behavioral and physiological
functions (McCall and Harris, 1988; Bagdy et al., 1989; Kozuru
et al., 2000). MDL100,907 (()--(2,3-dimethoxyphenyl)-1-[2-(4-
fluorophenylethyl)]-4-piperidinemethanol) is a 5-HT2A antagonist
(pKi  9.07) with a much lower affinity for 5-HT2C (pKi  7.06)
and adrenergic 1 receptors (pKi  6.89) (Kehne et al., 1996).
SB-242084 (6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-
pyridyl] carbamoyl]-indoline) is a 5-HT2C antagonist (pKi  9.0)
with a considerably lower affinity for other serotonergic and non-
serotonergic receptors (5-HT2B, pKi  7.0; 5-HT2A, pKi  6.8; 1
adrenergic, pKi  5.0) (Kennett et al., 1997). These two receptor
subtype antagonists can be used to dissect 5-HT2A versus 5-HT2C
receptor-mediated effects of ()DOI.
The hypothalamic paraventricular nucleus plays a crucial role
in mediating neuroendocrine responses to serotonergic activation
(Rittenhouse et al., 1993, 1994; Bagdy, 1996). The hypothalamic
paraventricular nucleus receives serotonergic projections from
the raphe nuclei, which also send collaterals to other limbic
structures, such as amygdala (Swanson and Sawchenko, 1983;
Liposits et al., 1987; Petrov et al., 1994). The hormone responses
to serotonergic stimulation reflect serotonergic function in the
hypothalamus.
()DOI increases the release of oxytocin, prolactin, ACTH,
corticosterone, and renin (Van de Kar et al., 1995a; Bagdy, 1996)
and also increases c-Fos expression in oxytocin and CRF cells in
the hypothalamic paraventricular nucleus (Van de Kar et al.,
2001). Both of the effects of ()DOI (intraperitoneally) can be
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blocked by the 5-HT2A antagonist MDL100,907 (subcutaneously)
(Van de Kar et al., 2001). Whether these effects of ()DOI result
from a direct activation of 5-HT2A receptors in the hypothalamic
paraventricular nucleus is not clear.
Autoradiographic and in situ hybridization studies have found
moderate densities of 5-HT2A/2C binding sites and 5-HT2A tran-
scripts in the hypothalamic paraventricular nucleus (Appel et al.,
1990; Wright et al., 1995; Gundlah et al., 1999). However, because
of a limited resolution of these approaches, the detailed cellular
distribution of 5-HT2A receptors in the paraventricular nucleus
remains unknown.
The present study, using immunohistochemistry, examined the
cellular distribution of 5-HT2A receptors in the hypothalamic para-
ventricular nucleus. Moreover, by microinjecting MDL100,907 or
SB-242084 into the paraventricular nucleus, the relative contribu-
tion of 5-HT2A versus 5-HT2C receptors in the nucleus to ()DOI-
induced neuroendocrine responses was examined. Our study pro-
vides the first evidence that the neuroendocrine responses to




Male Sprague Dawley rats (225–275 gm) were purchased from Harlan
Sprague Dawley (Indianapolis, IN). Before surgery, the rats were housed
two per cage in a temperature-, humidity-, and light-controlled room (12
hr light /dark cycle, lights on from 7:00 A.M. to 7:00 P.M.). After surgery,
the rats were housed one per cage in the same room. Food and water
were available ad libitum. All procedures were conducted in accordance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals as approved by Loyola University Institutional An-
imal Care and Use Committee.
Drugs
()DOI was purchased from Research Biochemicals (Natick, MA).
MDL100,907 was generously donated by Hoechst Marion Roussel Re-
search Institute (Cincinnati, OH). SB-242084 was generously donated by
GlaxoSmithKline Pharmaceuticals (Harlow, UK). Xylazine was pur-
chased from Phoenix Pharmaceuticals (St. Joseph, MO). Ketamine was
purchased from Fort Dodge Animal Health (Fort Dodge, IA). ()DOI
was dissolved in 0.9% saline at a concentration of 1 mg/ml. Both
MDL100,907 and SB-242084 were prepared by sonicating in a minimal
volume of 0.01N HCl containing 10% of 2-hydroxypropyl--cyclodextrin
(Sigma, St. Louis, MO) and further diluted to their final concentrations
with saline (0.748, 7.48, and 18.7 mM for MDL100,907; 10 mM for
SB-242084). The vehicle was the solvent used to dissolve the highest
concentration of MDL100,907 (18.7 mM). Ampicillin (Sigma) was dis-
solved in saline at a concentration of 50 mg/ml. Sulfamethoxazole and
trimethoprim (Alpharma USPD, Baltimore, MD) was suspended in
drinking water (4.2 mg of sulfamethoxazole and 0.85 mg of trimethoprim
in 250 ml of water). All solutions were made fresh before administration.
Surgery
Rats were anesthetized with a mixture of ketamine and xylazine (100
mg/kg ketamine plus 7 mg/kg xylazine, 1.4 ml/kg, i.p.). A double-
barreled guide cannula (26 gauge, 1.2 mm center-to-center distance) with
its corresponding dummy cannula inserted inside (Plastic One, Roanoke,
VA) was implanted into the brain above both sides of the paraventricular
nucleus according to the following stereotaxic coordinates: 5.7 mm
rostral, 0.6 mm lateral with respect to lambda, and 6.1 mm ventral from
the skull surface. Dehydration was prevented by injecting 1 ml of saline
(subcutaneously) after surgery. To prevent postsurgery infection, all rats
received ampicillin (50 mg/kg, s.c.) immediately after surgery, followed
by 6 d of administration of sulfamethoxazole and trimethoprim sus-
pended in the drinking water. Rats were not treated further for a
minimum of 10 d.
Experimental protocol
Rats were handled for 4 consecutive days before the experiment. On the
day of the experiment, rats were randomly assigned to different experi-
mental groups [eight rats for saline-challenged groups and 13–15 rats for
()DOI-challenged groups]. After removal of the dummy cannula, an
injection cannula (33 gauge, 1.2 mm center-to-center distance, 1.5 mm
projection from the tip of the guide cannula) was inserted through the
implanted double-barreled guide cannula to a position 1.5 mm ventral to
the tip of the guide cannula. Rats received an intra-paraventricular
microinjection (0.5 l /side) of the vehicle, increasing doses of
MDL100,907 (0.748, 7.48, and 18.7 nmol), or SB-242084 (10 nmol). The
drugs were microinjected over 1 min. The injection cannula was left in
situ for an additional 1 min before removal. Fifteen minutes after the
intra-paraventricular microinjections, the rats received an injection of
()DOI (1 mg/kg, s.c.) or saline (1 ml/kg, s.c.). The rats were killed by
decapitation 30 min after ()DOI injection. The blood was collected in
centrifuge tubes containing a 0.5 ml solution of 0.3 M EDTA, pH 7.4.
After centrifugation, the plasma was stored at 70°C for radioimmuno-
assays of plasma hormones. The brains were frozen on dry ice and saved
for a histological verification of the positions of the cannulas.
Histology
Coronal sections (30 M) were cut on a cryostat and mounted on
gelatin-coated slides. The slides were stained with cresyl violet, dehy-
drated, and coverslipped. The positions of the tips of the double-barreled
injection cannulas were inspected under a light microscope and photo-
graphed. Only animals with cannula positions immediately dorsal to the
hypothalamic paraventricular nucleus and with intact neurons in the
nucleus were used for data analysis (see Fig. 1).
Radioimmunoassay
Plasma ACTH, corticosterone, oxytocin, and prolactin concentrations
were determined by radioimmunoassays as described in detail previously
(Li et al., 1993, 1997). Plasma renin activity (PRA) was determined as
the ability of renin to generate angiotensin I from endogenous substrate.
Plasma renin concentration (PRC) was determined as the generation of
angiotensin I by endogenous renin from a saturating amount of added
renin substrate. Both PRA and PRC were measured as described previ-
ously (Richardson Morton et al., 1989).
Immunohistochemical labeling of 5-HT2A receptors
Tissue preparation. Three Sprague Dawley rats (225–275 gm) were deeply
anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and then per-
fused intracardially through the ascending aorta first with 0.01 M PBS,
pH 7.4, followed by 0.1 M phosphate-buffered 4% formaldehyde, pH 7.4.
The brains were removed and postfixed for 2 hr at 4°C in the above
fixative solution and then cryoprotected for 24 hr in 0.01 M PBS buffer,
pH 7.4, containing 30% sucrose before sectioning. Serial coronal sections
of the hypothalamus (30 M) were cut with a freezing microtome and
transferred into 0.01 M PBS buffer, pH 7.4, and stored at 4°C.
Immunohistochemistry. Free-floating sections were exposed to micro-
wave radiation (400 W, 15 sec). After cooling, sections were treated with
0.2% Triton X-100 (Fisher Scientific, Hanover Park, IL) for 40 min and
rinsed three times in PBS buffer (Fritschy et al., 1998). The endogenous
hydrogen peroxidase was inactivated by treating the sections with 3%
hydrogen peroxide for 10 min. Nonspecific binding of the antibodies was
reduced by preincubating the sections in 5% normal horse serum diluted
in PBS for 1 hr at room temperature. The blocking serum was also used
as diluents for antibody preparations. The sections were incubated over-
night at room temperature with a monoclonal mouse anti-5-HT2A IgG
(1:150 dilution; PharMingen, San Diego, CA). After washing in PBS, the
sections were incubated with biotinylated horse anti-mouse IgG (1:2000
dilution; Vector Laboratories, Burlingame, CA) for 1 hr at room tem-
perature, followed by PBS washing. Subsequently, the sections were
incubated with avidin–biotinylated peroxidase complex (ABC; dilution,
1:200; Vector Laboratories) for 40 min, followed by PBS washing. Before
the peroxidase reaction, the sections were transferred for 5 min into 0.05
M Tris-buffered saline (TBS), pH 7.4. The peroxidase reaction was
performed by incubating the sections in 0.05 M Tris-HCl containing
0.02% (w/v) 3,3-diaminobenzidine tetrahydrochloride (DAB) in the
presence of ammonium nickel sulfate (0.25%) and 0.002% (v/v) hydro-
gen peroxide. When the intensity of the signal was optimal, the reaction
was stopped by rinsing the sections in TBS buffer. The resulting nickel-
DAB polymer was further silver intensified in a solution containing 0.1%
silver nitrate, 0.1% ammonium nitrate, 1% silicotungstic acid, and 0.2%
formaldehyde for 2–3 min, and the reaction was stopped by rinsing in 1%
acetic acid. Finally, the sections were rinsed, mounted on gelatin-coated
slides, dehydrated, and coverslipped for light microscopy and photomi-
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crography. The images were scanned and analyzed using Adobe Photo-
shop software (Adobe Systems, San Jose, CA). Four rostrocaudal levels
of the hypothalamic paraventricular nucleus were examined. These ros-
trocaudal levels are based on the book by Swanson (1992).
Control experiment. The control sections were treated exactly in the
same way as the experimental sections, except that the primary antibody
was replaced with the diluents of the primary antibody.
Statistical analyses
The hormone data are presented as group means and the SEM and
analyzed by two-way ANOVA. Post hoc tests were conducted using
Newman–Keuls multiple-range test. A computer program (GB STAT;
Dynamic Microsystems, Silver Spring, MD) was used for the statistical
analyses.
RESULTS
Histological verification of the position of
double-barreled injection cannula
Figure 1 is a representative picture showing the double-barreled
cannula tracts terminating bilaterally at the dorsal border of the
hypothalamic paraventricular nucleus. The border of the hypo-
thalamic paraventricular nucleus and the neurons in the hypotha-
lamic paraventricular nucleus were intact, indicating no damage
in the nucleus. Histological examination of the ()DOI-
challenged rats indicated that 85% (63 of 74) had correct cannula
positions and no damage to the neurons of the hypothalamic
paraventricular nucleus. The saline-challenged rats and the
()DOI-challenged rats with verified cannula positions were used
for the statistical evaluation of hormone data.
Microinjection of MDL100,907 into the hypothalamic
paraventricular nucleus inhibits oxytocin and prolactin
responses to ()DOI
Microinjection of increasing doses of MDL100,907 into the hy-
pothalamic paraventricular nucleus did not affect basal levels of
oxytocin and prolactin but inhibited ()DOI-induced oxytocin
and prolactin release in a dose-dependent manner (Fig. 2). For
plasma oxytocin, the two-way ANOVA indicated a significant
main effect of ()DOI (F(1,68)  61.00; p  0.0001) and a
significant main effect of MDL100,907 (F(3,68)  11.04; p 
0.0001). There was a significant interaction between ()DOI and
MDL100,907 (F(3,68)  13.11; p  0.0001). The post hoc New-
man–Keuls test indicated that ()DOI significantly increased
plasma oxytocin levels in rats receiving vehicle or the lowest dose
of MDL100,907. All three doses of MDL100,907 (0.748, 7.48, and
18.7 nmol) significantly inhibited (26, 72, and 92%, respectively)
the oxytocin response to ()DOI.
For plasma prolactin, the two-way ANOVA indicated a signif-
icant main effect of ()DOI (F(1,68)  22.65; p  0.0001) and
MDL100,907 (F(3,68)  10.24; p  0.0001). There was a significant
interaction between ()DOI and MDL100,907 (F(3,68)  9.60;
p  0.0001). The post hoc Newman–Keuls test indicated that
()DOI significantly increased the plasma level of prolactin in
rats receiving vehicle or the lowest dose of MDL100,907.
MDL100,907 inhibited ()DOI-induced prolactin release by
56% at the dose of 0.748 nmol, 98% at the dose of 7.48 nmol, and
100% at the dose of 18.7 nmol.
Microinjection of MDL100,907 into the hypothalamic
paraventricular nucleus inhibits ACTH but not
corticosterone response to ()DOI
Injection of MDL100,907 into the hypothalamic paraventricular
nucleus did not produce a significant change in basal plasma
ACTH level. ()DOI-induced ACTH release was dose-
dependently inhibited by MDL100,907 microinjected into the
hypothalamic paraventricular nucleus (Fig. 3A). The two-way
ANOVA indicated a significant main effect of ()DOI (F(1,68) 
82.58; p  0.0001) and a significant main effect of MDL100,907
(F(3,68)  16.33; p  0.0001). The interaction between ()DOI
and MDL100,907 was also significant (F(3,68)  15.48; p 
0.0001). The post hoc Newman–Keuls test indicated that ()DOI
significantly increased plasma ACTH levels in rats receiving
Figure 1. Histological verification of the position of the tips of the
double-barreled injection cannula (30 m; cresyl violet staining). Arrows,
The tips of a double-barreled cannula. PVN, The hypothalamic paraven-
tricular nucleus; V, the 3rd ventricle.
Figure 2. Dose-dependent inhibition of oxytocin (A) and prolactin (B)
responses to ()DOI by MDL100,907 microinjected into the hypotha-
lamic paraventricular nucleus. The data represent the mean  SEM of
7–14 rats per group. *p  0.05, **p  0.01, significant effect of ()DOI
compared with the saline challenge group. #p  0.05, ##p  0.01,
significant effect of MDL100,907 compared with the vehicle–()DOI
group (two-way ANOVA and Newman–Keuls multiple range test). Veh,
Vehicle; PVN, the hypothalamic paraventricular nucleus.
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vehicle or the lowest dose of MDL100,907. MDL100,907 inhib-
ited ()DOI-induced ACTH release by 42% at 0.748 nmol, 83%
at 7.48 nmol, and 88% at 18.7 nmol.
For plasma corticosterone, the two-way ANOVA indicated a
significant main effect of ()DOI (F(1,68)  73.65; p  0.0001) and
a significant main effect of MDL100,907 (F(3,68)  2.95; p  0.05).
The interaction between ()DOI and MDL100,907 was not sig-
nificant (F(3,68)  2.38; p  0.0771). The post hoc Newman–Keuls
test indicated that microinjection of MDL100,907 into the hypo-
thalamic paraventricular nucleus did not change the basal cortico-
sterone level. Whereas ()DOI significantly elevated plasma cor-
ticosterone, the corticosterone response to ()DOI was not
inhibited by any of the three doses of MDL100,907 microinjected
into the hypothalamic paraventricular nucleus (Fig. 3B).
Microinjection of MDL100,907 into the hypothalamic
paraventricular nucleus inhibits the renin response to
()DOI
Injection of MDL100,907 into the hypothalamic paraventricular
nucleus did not alter basal renin activity or renin concentration.
Both plasma renin activity and renin concentration were increased
after ()DOI challenge. This effect of ()DOI was dose-
dependently inhibited by increasing doses of MDL100,907 micro-
injected into the hypothalamic paraventricular nucleus (Fig. 4).
The two-way ANOVA indicated a significant main effect of
()DOI on renin activity (F(1,68)  42.13; p  0.0001) and renin
concentration (F(1,68)  62.06; p  0.0001). The main effect of
MDL100,907 was also significant for both renin activity (F(3,68) 
10.37; p  0.0001) and renin concentration (F(3,68)  9.16; p 
0.0001). There was a significant interaction between ()DOI and
MDL100,907 for renin activity (F(3,68)  6.66; p  0.0005), as well
as for renin concentration (F(3,68)  8.23; p  0.0001). The post hoc
Newman–Keuls test indicated that the three doses of MDL100,907
(0.748, 7.48, and 18.7 nmol) inhibited the ()DOI-induced in-
crease in plasma renin activity by 58, 90, and 92%, respectively.
Similarly, the ()DOI-induced increase in renin concentration was
inhibited by 37, 77, and 87%, respectively (Fig. 4).
Microinjection of SB-242084 into the hypothalamic
paraventricular nucleus does not inhibit
neuroendocrine responses to ()DOI
Microinjection of SB-242084 (10 nmol) into the hypothalamic
paraventricular nucleus did not alter basal plasma levels of oxy-
tocin, prolactin, ACTH, corticosterone, renin activity, or renin
concentration (Fig. 5). The plasma levels of all of the hormones
were elevated by ()DOI challenge (Fig. 5).
()DOI-induced oxytocin (Fig. 5A) and prolactin (Fig. 5B)
release were not inhibited by an intra-paraventricular microinjec-
tion of SB-242084. The two-way ANOVA indicated a significant
main effect of ()DOI on oxytocin (F(1,36)  42.16; p  0.0001)
and prolactin (F(1,36)  41.86; p  0.0001). There was no signif-
icant main effect of SB-242084 on oxytocin (F(1,36)  0.1039; p 
0.7491) or prolactin (F(1,36)  0.90; p  0.3499). The interaction
between ()DOI and SB-242084 was not significant for oxytocin
(F(1,36)  0.00162; p  0.681) or prolactin (F(1,36)  0.63; p 
0.4327).
SB-242084 microinjected into the hypothalamic paraventricular
nucleus did not inhibit the ACTH (Fig. 5C) or corticosterone
Figure 3. Microinjection of MDL100,907 into the hypothalamic para-
ventricular nucleus dose-dependently inhibits ACTH (A) but not corti-
costerone (B) responses to ()DOI. The data represent the mean  SEM
of 7–14 rats per group. *p  0.05, **p  0.01, significant effect of ()DOI
compared with the saline challenge group. ##p  0.01, significant effect
of MDL100,907 compared with the vehicle–()DOI group (two-way
ANOVA and Newman–Keuls multiple range test). Veh, Vehicle; PVN,
the hypothalamic paraventricular nucleus.
Figure 4. Microinjection of MDL100,907 into the hypothalamic para-
ventricular nucleus dose-dependently inhibited ()DOI-induced increase
in renin activity ( A) and renin concentration (B). The data represent the
mean  SEM of 7–14 rats per group. **p  0.01, significant effect of
()DOI compared with the saline challenge group. ##p  0.01, signifi-
cant effect of MDL100,907 compared with the vehicle–()DOI group
(two-way ANOVA and Newman–Keuls multiple range test). Veh, Vehi-
cle; PVN, the hypothalamic paraventricular nucleus.
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(Fig. 5D) responses to ()DOI challenge. The two-way ANOVA
indicated a significant main effect of ()DOI on ACTH (F(1,36) 
54.28; p  0.0001) and corticosterone (F(1,36)  62.6; p  0.0001).
No significant main effect of SB-242084 was observed for ACTH
(F(1,36)  1.16; p  0.2889) or corticosterone (F(1,36)  2.59; p 
0.1164). There was no significant interaction between ()DOI
and SB-242084 for ACTH (F(1,36)  1.67; p  0.2044) or corti-
costerone (F(1,36)  0; p  0.9996).
Similarly, SB-242084 did not inhibit the renin response to
()DOI when microinjected into the hypothalamic paraventricu-
lar nucleus (Fig. 5E,F). The two-way ANOVA indicated a sig-
nificant main effect of ()DOI on renin activity (F(1,36)  63.52;
p  0.0001) and renin concentration (F(1,36)  68.06; p  0.0001).
There was no significant main effect of SB-242084 on renin
activity (F(1,36)  0.90; p  0.3494) or on renin concentration
(F(1,36)  0.00342; p  0.9537). The interaction between ()DOI
and SB-242084 was not significant for renin activity (F(1,36) 
0.40; p  0.5325) or renin concentration (F(1,36)  0.32; p 
0.5767).
Immunohistochemical staining of 5-HT2A receptors in
the hypothalamic paraventricular nucleus
In the hypothalamic paraventricular nucleus, 5-HT2A receptor-
immunoreactive perikarya were heterogeneously distributed
throughout the nucleus (Fig. 6A–D). A high density of the label-
ing was found in the anterior and posterior magnocellular re-
gions. A moderate density of labeling was found in the medial and
dorsal parvicellular regions. As a positive control, we observed a
typical distribution of 5-HT2A receptor immunoreactivity in the
cortex; the majority of the staining was localized to pyramidal
cells and the apical dendrites of pyramidal cells (Fig. 6F). No
staining was observed in the absence of primary anti-5-HT2A
receptor antibody (Fig. 6G).
DISCUSSION
The present study provides immunohistochemical and pharma-
cological evidence demonstrating that peripheral administration
of the 5-HT2A/2C agonist ()DOI primarily activates 5-HT2A
receptors in the hypothalamic paraventricular nucleus, leading to
the release of oxytocin, ACTH, prolactin, and renin into the
circulation.
The hypothalamic paraventricular nucleus is an integral part of
the limbic system (Saphier and Feldman, 1986; Herman and
Cullinan, 1997) and participates in mood modulation (Legros,
1992; Bernstein et al., 1998; Scott and Dinan, 1998). Many de-
pressed patients have high plasma levels of cortisol, suggesting a
disrupted regulation of the hypothalamic–pituitary–adrenal axis
(Sherman and Pfohl, 1985; Barden et al., 1995). A larger density
of oxytocin- and vasopressin-expressing neurons was found in the
hypothalamic paraventricular nucleus in postmortem brains of
depressed patients (Purba et al., 1996). For many years, psychia-
trists have administered serotonin agonists to depressed patients
to determine whether the hormone responses can provide a
peripheral diagnostic tool of the functioning of serotonin recep-
tors in the hypothalamus. Our study demonstrates in rats that
hormone responses to a 5-HT2A/2C agonist are primarily medi-
ated by activation of 5-HT2A receptors in the hypothalamic para-
ventricular nucleus.
Injection of 2.5 mg/kg ()DOI increases plasma levels of
oxytocin, prolactin, ACTH, corticosterone, and renin (Van de
Kar et al., 2001). This effect of ()DOI can be blocked by the
5-HT2A antagonist MDL100,907 but not by SB-242084, indicating
an activation of 5-HT2A receptors (Van de Kar et al., 2001;
Hemrick-Luecke and Evans, 2002). A dose of 1 mg/kg of the
bioactive isomer ()DOI is equivalent to 2.5 mg/kg ()DOI in
producing a similar degree of elevation of plasma hormones (M.
Shankaran, G. Battaglia, D. D’Souza, Y. Zhang, and L. D. Van de
Kar, unpublished observations). Thus, we chose 1 mg/kg (subcu-
taneously) as the challenge dose of ()DOI to examine the
function of 5-HT2A receptors.
Until recently, differentiation between 5-HT2A and 5-HT2C
receptor-mediated effects was hindered by a lack of receptor
subtype-selective antagonists. Many available 5-HT2 antagonists,
Figure 5. Microinjection of SB-242084 into the hypothalamic paraven-
tricular nucleus does not inhibit the neuroendocrine responses to
()DOI. The data represent the mean  SEM of 7–14 rats per group.
**p  0.01, significant effect of ()DOI compared with the saline chal-
lenge groups (two-way ANOVA and Newman–Keuls multiple range test).
Veh, Vehicle; SB, SB-242084; PVN, the hypothalamic paraventricular
nucleus.
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such as ketanserin and ritanserin, have a high affinity for both
5-HT2A and 5-HT2C receptors (Leysen et al., 1985; Van Wijn-
gaarden et al., 1990). MDL100,907 is a 5-HT2A antagonist with
100-fold higher affinity for 5-HT2A than 5-HT2C receptors and a
low affinity for dopamine D2 receptors (Kehne et al., 1996).
SB-242084 is a 5-HT2C antagonist with a low affinity for other
serotonin and nonserotonin receptors (Kennett et al., 1997).
Because of its low solubility, the highest dose of SB-242084
injected into the rats was 10 nmol. Still, 7.48 nmol of MDL100,907
produced a 70% inhibition of hormone responses to ()DOI
(Figs. 3–5), whereas no inhibition was observed by 10 nmol of
SB-242084. Thus, the hormone responses to ()DOI are medi-
ated by 5-HT2A receptors in the hypothalamic paraventricular
nucleus.
The importance of the hypothalamic paraventricular nucleus in
the neuroendocrine response to serotonergic stimulation has
been established mainly via lesion studies (Rittenhouse et al.,
1992; Bagdy and Makara, 1994; Bagdy, 1996). These lesions
destroyed all of the cells (i.e., oxytocin and CRF cells) in the
hypothalamic paraventricular nucleus and therefore cannot be
used to examine the function of a particular type of receptor in
the nucleus. In our experiment, a double-barreled cannula chron-
ically implanted above both sides of the hypothalamic paraven-
tricular nucleus produced no damage to the neurons in the
nucleus. This microinjection technique allowed us to examine
specifically which receptor subtype in the hypothalamic paraven-
tricular nucleus mediates hormone responses to ()DOI.
One concern regarding microinjection technique is the accu-
racy of injection and the degree of drug diffusion from the
injection site. To ensure the accuracy of injection, the tips of
injection cannulas were histologically verified. In a preliminary
experiment, the diffusion pattern of fast green dye microinjected
using the same experimental protocol was examined. The green
dye primarily localized in the hypothalamic paraventricular nu-
cleus, with limited diffusion to surrounding nuclei. Moreover, the
nuclei neighboring the hypothalamic paraventricular nucleus are
not involved in the serotonergic stimulation of hormone release
(Richardson Morton et al., 1989; Rittenhouse et al., 1992, 1993;
Bagdy, 1996). Thus, diffusion of the antagonist into regions sur-
rounding the paraventricular nucleus would not confound the
results of the present study. For example, the supraoptic nucleus
has a high density of oxytocin cells and 5-HT2A receptor immu-
noreactivity. However, lesions in the supraoptic nucleus do not
inhibit the release of oxytocin by serotonergic stimulation (Van
de Kar et al., 1995b). Lesions in the ventromedial nucleus and
dorsomedial nucleus do not affect the release of prolactin and
Figure 6. 5-HT2A receptor immunoreactivity in the hypothalamic paraventricular nucleus (PVN ). V denotes the 3rd ventricle. The numbers indicate the
rostrocaudal distance from bregma (Swanson, 1992). A–D, Distribution of 5-HT2A receptor immunoreactivity in the hypothalamic paraventricular
nucleus. Scale bar, 100 m. E, High magnification of C. Scale bar, 10 m. F, 5-HT2A receptor immunoreactivity in cerebral cortex. Arrows, Pyramidal
neurons; arrowheads, apical dendrites of pyramidal neurons. Scale bar, 10 m. G, No 5-HT2A receptor-like immunoreactivity was observed in the
hypothalamic paraventricular nucleus in the absence of primary antibody. Scale bar, 100 m.
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renin after serotonergic stimulation (Rittenhouse et al., 1992).
Although stimulation of neurons in the dorsomedial nucleus
increases ACTH release (Stotz-Potter et al., 1996; Bailey and
DiMicco, 2001), we did not detect 5-HT2A receptor labeling in the
dorsomedial nucleus. Thus, it is not likely that the dorsomedial
nucleus contributes to ()DOI-induced release of ACTH.
In this study, we measured a wide range of hormones that use
different regulatory mechanisms and signaling cascades. The oxy-
tocin cells in the hypothalamic paraventricular nucleus send their
axons to the posterior lobe of the pituitary, directly releasing
oxytocin into the bloodstream. ACTH and prolactin are released
by corticotrophs and lactotrophs, respectively, in the anterior lobe
of the pituitary and are under the regulation of releasing and/or
inhibiting hormones from the hypothalamus. Thus, compared
with oxytocin, ACTH and prolactin represent amplified indices
subsequent to hypothalamic activation. Corticosterone, released
from the adrenal cortex via stimulation by ACTH, is the most
amplified signal of hypothalamic activation. Renin is released
from the kidney by stimulation of the sympathetic nervous system
and an endocrine renin-releasing factor (Urban et al., 1992). The
hypothalamic paraventricular nucleus is a part of the complex
system that regulates renin release (Van de Kar et al., 1987; Van
de Kar and Blair, 1999). Because a majority of the hormones
released by ()DOI was inhibited by intra-paraventricular
MDL100,907, activation of 5-HT2A receptors in the hypothalamic
paraventricular nucleus represents the common mechanism un-
derlying hormone responses to ()DOI.
A difference in amplification of various hormones can be ob-
served by comparing their degrees of inhibition by MDL100,907.
A dose of 18.7 nmol of MDL100,907 completely blocked the
oxytocin and prolactin responses to ()DOI, whereas the same
dose of MDL100,907 produced 90% inhibition of renin activity,
renin concentration, and ACTH. Corticosterone is most ampli-
fied through the hypothalamus–pituitary–adrenal axis. A plasma
concentration of ACTH 200 pg/ml would be sufficient to drive
a maximal release of corticosterone (Rittenhouse et al., 1994;
Levy et al., 1994; Bagdy, 1996). We found that the highest dose of
MDL100,907 (18.7 nmol) lowered ()DOI-increased plasma
level of ACTH from 769 to 193 pg/ml. Accordingly, the cortico-
sterone response to ()DOI was not inhibited by intra-
paraventricular injection of MDL100,907.
Another reason why intra-paraventricular injection of
MDL100,907 produced a lower degree of inhibition on plasma
ACTH response to ()DOI is that ()DOI may activate neurons
in other nuclei, such as the amygdala, that are also involved in
ACTH release (Beaulieu et al., 1986; Feldman et al., 1998). In
addition, the corticosterone response to an acute injection of DOI
may also involve direct effects on the adrenal gland (Alper, 1990;
Rittenhouse et al., 1994). Thus, it is not unexpected that the
inhibitory effect of intra-paraventricular injection of MDL100,907
on ()DOI-induced hormone release was observed for all of the
other hormones except corticosterone.
Although the presence of 5-HT2A receptors in the hypotha-
lamic paraventricular nucleus has been demonstrated by in situ
hybridization, autoradiographic studies, and Western blot analy-
sis (Appel et al., 1990; Wright et al., 1995; Gundlah et al., 1999),
conventional immunohistochemistry failed to label 5-HT2A re-
ceptors in the nucleus. This suggests that 5-HT2A receptor
epitopes in the hypothalamic paraventricular nucleus are not
readily accessible in situ. In the present study, we adapted antigen
retrieval procedures based on microwave irradiation to enhance
the immunohistochemical staining of 5-HT2A receptors (Fritschy
et al., 1998). The microwave irradiation procedure did not affect
the immunostaining pattern of 5-HT2A receptors reported in
other brain regions, such as the cortex (Willins et al., 1997;
Cornea-Hébert et al., 1999). The negative control sections, as
defined by the lack of primary antibody, did not exhibit 5-HT2A
receptor immunoreactivity. Therefore, the 5-HT2A receptor im-
munopositive perikarya in the hypothalamic paraventricular nu-
cleus most likely represent specific labeling of 5-HT2A receptors.
5-HT2A receptor immunopositive perikarya were heteroge-
neously distributed in the hypothalamic paraventricular nucleus,
including the regions that are known to express oxytocin and
CRF cells (Sawchenko and Swanson, 1985). Our recent immuno-
fluorescence studies show that 5-HT2A receptors are present on
oxytocin-containing cells (Zhang et al., 2001). Thus, it is possible
that 5-HT2A receptors are located on oxytocin, CRF, and/or
other neurons in the hypothalamic paraventricular nucleus.
In summary, 5-HT2A receptor immunoreactivity was found in
the hypothalamic paraventricular nucleus in which CRF and
oxytocin cells are located. Neuroendocrine responses to ()DOI
were dose-dependently inhibited by intra-paraventricular injec-
tion of the 5-HT2A antagonist MDL100,907 but not by the
5-HT2C antagonist SB-242084. Thus, neuroendocrine responses
to ()DOI can be used as a peripheral indicator of the function
of 5-HT2A receptors in the hypothalamic paraventricular nucleus.
This study provides valuable information for the possible devel-
opment of neuroendocrine challenge tests for patients suffering
from mood disorders.
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